Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503990 | 1.00 | CYP19A1 (0.43) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL30589181 | 0.89 | CYP19A1 (0.50) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL24608491 | 0.89 | CYP19A1 (0.50) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL30431325 | 0.74 | CYP19A1 (0.47) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL21457779 | 0.74 | CYP19A1 (0.47) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL8067804 | 0.74 | CYP3A4 (0.42) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL11147179 | 0.73 | KCNA5 (0.47) | CYP19A1CYP3A4CYP3A5CYP1A2CYP11B1 | |
| SCHEMBL9770755 | 0.73 | CYP3A4 (0.43) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 | |
| SCHEMBL8606933 | 0.73 | CYP19A1 (0.50) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL30048933 | 0.73 | CYP19A1 (0.50) | CYP19A1CYP3A4CYP3A5LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| EP-3976189-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| EP-3976189-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos N.V. (BE) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020239658-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1B, IL1A, IL36G | CYP19A1 138/4885CYP3A4 2032/4885CYP3A5 1077/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | CYP19A1 211/4885CYP3A4 1055/4885CYP3A5 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.